1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Geodon (ziprasidone; Pfizer/Meiji Seika) is a 5-HT2A/D2 antagonist, with greater affinity for 5-HT2A than D2. With agonism at the 5-HT1A receptor, Geodon has questionable effects on improving the negative and cognitive symptoms. The drug has no appreciable affinity for M1 or M3 muscarinic receptors, and is associated with low overall effects to weight and metabolic functions. With oral and IM formulations available, Geodon can be used in acute and maintenance treatment settings.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Geodon including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Geodon for the top five countries from 2012 to 2022.
- Sales information covered for the US, Germany, Italy, Spain and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Geodon performance
- Obtain sales forecast for Geodon from 2012-2022 in the top five countries (the US, Germany, Italy, Spain and Japan)

Table Of Contents

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 14
4.1 Diagnosis 14
4.1.1 Subjective Assessments 15
4.1.2 Disease Subtypes 16
4.2 Treatment Overview 19
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 21
4.2.2 Maintenance Treatment of Schizophrenia 22
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Geodon (ziprasidone hydrochloride) 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 27
6.4 SWOT Analysis 28
6.5 Forecast 28
7 Appendix 29
7.1 Bibliography 29
7.2 Abbreviations 31
7.3 Methodology 32
7.4 Forecasting Methodology 32
7.4.1 Diagnosis and Treatment Rates 32
7.4.2 Adherence Rates 33
7.4.3 General Pricing Assumptions 33
7.4.4 Drug Assumptions 34
7.4.5 Generic Erosion 35
7.5 Key Opinion Leaders 36
7.6 About the Authors 37
7.6.1 Author 37
7.6.2 Reviewers 37
7.6.3 Global Head of Healthcare 38
7.7 About GlobalData 39
7.8 Disclaimer 39

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 13
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 16
Table 3: Development-Based Classification of Antipsychotic Drugs 19
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 20
Table 5: Guidelines for the Treatment of Schizophrenia 21
Table 6: Leading Branded Treatments for Schizophrenia, 2013 25
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 25
Table 8: Product Profile - Geodon 26
Table 9: Geodon SWOT Analysis, 2013 28
Table 10: Global Sales Forecasts ($m) for Geodon, 2012-2022 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Antipsychotic

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.